This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on april 1, 2020.Upon further investigation of the reported event, the following information is new and/or changed: h6 (identification of evaluation codes 10, 11, 3331, 213, 67).Method code #1: 10 - testing of actual/suspected device.Method code #2: 11 - testing of device from same lot/batch retained by manufacturer.Method code #3: 3331 - analysis of production records.Results code: 213 - no device problem found.Conclusions code: 67 - no problem detected.The actual sample was returned for investigation and photos taken upon receipt showed that a blood clot had been formed.However, it was not determined when the clot formed.The sample, after having been rinsed and dried was tested for its gas transfer performance and no anomalies were revealed with the obtained values meeting the factory specifications.Subsequently, bovine blood was circulated in the circuit while the pressure drop was determined.The obtained values were confirmed to meet the factory's specifications and no obstruction was confirmed.During the blood circulation, the appearance of dark colored spots inside the oxygenator as indicated in the complaint was not reproduced.A physiological saline solution was then flowed into the blood channel and no formation of blood clots were visually observed.Device history record and incoming inspection record from the involved product/lot number combination were reviewed and confirmed with no anomaly.The investigation results verified that the actual sample, after having been rinsed, was the normal product with no issue in the gas transfer performance and the pressure drop.All available information has been placed on file in quality management for appropriate tracking, trending and follow-up.
|